Glaukos (NYSE: GKOS) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its competitors? We will compare Glaukos to related businesses based on the strength of its institutional ownership, earnings, dividends, valuation, profitability, analyst recommendations and risk.
Institutional and Insider Ownership
99.2% of Glaukos shares are held by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 16.4% of Glaukos shares are held by company insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Glaukos and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Glaukos has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Glaukos’ competitors have a beta of 0.47, suggesting that their average share price is 53% less volatile than the S&P 500.
This is a summary of current recommendations and price targets for Glaukos and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Glaukos currently has a consensus price target of $47.50, indicating a potential upside of 86.06%. As a group, “Medical Devices & Implants” companies have a potential upside of 36.41%. Given Glaukos’ stronger consensus rating and higher possible upside, equities analysts clearly believe Glaukos is more favorable than its competitors.
Valuation & Earnings
This table compares Glaukos and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Glaukos||$114.40 million||$4.52 million||-638.09|
|Glaukos Competitors||$1.67 billion||$207.58 million||86.11|
Glaukos’ competitors have higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Glaukos beats its competitors on 10 of the 13 factors compared.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.